| http://purl.uniprot.org/citations/30334452 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/30334452 | http://www.w3.org/2000/01/rdf-schema#comment | "Although platinum-based chemotherapies have long been used as standard treatment in ovarian cancer, cisplatin resistance is a major problem that restricts its use. Herein, we investigate the biological function of SLC27A2 and its underlying mechanisms in regulating chemo-resistance in ovarian cancer. The findings show that SLC27A2 down-regulation in primary ovarian cancer tissues correlates with chemo-resistance and poor patient survival in our patient cohort. Significantly, we demonstrate that up-regulation of SLC27A2 by lentivirus-mediated p-SLC27A2 sensitizes ovarian cancer cells to cisplatin in vitro and in vivo via apoptosis. Mechanistic investigation reveals that miR-411 is the most strikingly over-expressed gene in response to ectopic expression of SLC27A2, but under-expressed in recurrent ovarian cancer tissues. Lower miR-411 expression contributes to ovarian cancer chemo-resistance in vitro and in vivo. Furthermore, SLC27A2 directly binds specific sites in the miR-411 promoter region and promoter activity decreases after mutation of putative SLC27A2-binding sites. This indicates that SLC27A2 is required for the transcriptional induction of miR-411. The luciferase assays also confirm that miR-411 directly targets ABCG2 in ovarian cancer, and overall findings establish the SLC27A2-miR-411-ABCG2 pathway in the regulation of ovarian cancer chemo-resistance with potential therapeutic applications."xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.org/dc/terms/identifier | "doi:10.4149/neo_2018_180122n48"xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/author | "Chen H.H."xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/author | "Zheng X.Y."xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/author | "Chen F.D."xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/author | "Zheng L.R."xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/author | "Ke S.C."xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/date | "2018"xsd:gYear |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/name | "Neoplasma"xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/pages | "915-924"xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/title | "SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer."xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://purl.uniprot.org/core/volume | "65"xsd:string |
| http://purl.uniprot.org/citations/30334452 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/30334452 |
| http://purl.uniprot.org/citations/30334452 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/30334452 |
| http://purl.uniprot.org/uniprot/#_O35488-mappedCitation-30334452 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30334452 |
| http://purl.uniprot.org/uniprot/#_Q3UNR3-mappedCitation-30334452 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30334452 |
| http://purl.uniprot.org/uniprot/#_Q3TN99-mappedCitation-30334452 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30334452 |
| http://purl.uniprot.org/uniprot/O35488 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/30334452 |
| http://purl.uniprot.org/uniprot/Q3UNR3 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/30334452 |
| http://purl.uniprot.org/uniprot/Q3TN99 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/30334452 |